| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Jr | |
| John C Burnett | |||
| Aderville Cabassi | |||
| Valentina Cannone | |||
| Riccardo Volpi | |||
| P2860 | cites work | Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association | Q22241921 |
| Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure | Q22306384 | ||
| A familial mutation renders atrial natriuretic Peptide resistant to proteolytic degradation | Q24657949 | ||
| Angiotensin-neprilysin inhibition versus enalapril in heart failure | Q28247091 | ||
| Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 | Q28511676 | ||
| Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A | Q28511919 | ||
| A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions | Q33577067 | ||
| Adiponectin-mediated modulation of hypertrophic signals in the heart | Q33688678 | ||
| Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms | Q33688706 | ||
| Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. | Q33698918 | ||
| Roles of atrial natriuretic peptide and its therapeutic use | Q34140971 | ||
| Impact of obesity on plasma natriuretic peptide levels | Q34295497 | ||
| Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure | Q61795227 | ||
| Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association | Q63353448 | ||
| Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy | Q81441501 | ||
| Multicenter prospective investigation on efficacy and safety of carperitide as a first-line drug for acute heart failure syndrome with preserved blood pressure: COMPASS: Carperitide Effects Observed Through Monitoring Dyspnea in Acute Decompensated | Q82194379 | ||
| The metabolic syndrome | Q82681399 | ||
| Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes | Q83321742 | ||
| Improved Insulin Sensitivity With Angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension | Q88164195 | ||
| Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study | Q90300274 | ||
| Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays | Q92533299 | ||
| Impaired atrial natriuretic peptide-mediated lipolysis in obesity. | Q42484201 | ||
| A new role for the natriuretic peptides: metabolic regulators of the adipocyte | Q42761019 | ||
| Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy | Q44734559 | ||
| Prognostic value of the metabolic syndrome in essential hypertension | Q44897345 | ||
| Visceral fat in hypertension: influence on insulin resistance and beta-cell function | Q44985642 | ||
| Potential U.S. Population Impact of the 2017 American College of Cardiology/American Heart Association High Blood Pressure Guideline | Q45072862 | ||
| Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. | Q45291593 | ||
| Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study | Q46350592 | ||
| A favorable cardiometabolic profile is associated with the G allele of the genetic variant rs5068 in African Americans: The Multi-Ethnic Study of Atherosclerosis (MESA). | Q47099891 | ||
| Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure | Q47705098 | ||
| Natriuretic peptides promote glucose uptake in a cGMP-dependent manner in human adipocytes. | Q48215808 | ||
| Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals | Q48252371 | ||
| Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse | Q48305832 | ||
| 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clini | Q50043295 | ||
| Atrial natriuretic peptide inhibits the production of adipokines and cytokines linked to inflammation and insulin resistance in human subcutaneous adipose tissue | Q57420152 | ||
| Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population | Q61663352 | ||
| Obesity-associated hypertension: new insights into mechanisms. | Q34374149 | ||
| Atrial natriuretic peptide and adiponectin interactions in man | Q34391434 | ||
| Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals | Q34459136 | ||
| Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response | Q34575644 | ||
| Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease | Q34714245 | ||
| A genetic variant of the atrial natriuretic peptide gene is associated with left ventricular hypertrophy in a non-diabetic population--the Malmö preventive project study | Q34782910 | ||
| Atrial natriuretic peptide and type 2 diabetes development--biomarker and genotype association study | Q35106848 | ||
| A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. | Q35283673 | ||
| Circulating atrial natriuretic peptide genetic association study identifies a novel gene cluster associated with stroke in whites | Q35294797 | ||
| A Novel Atrial Natriuretic Peptide Based Therapeutic in Experimental Angiotensin II Mediated Acute Hypertension | Q35659994 | ||
| Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study | Q35744489 | ||
| Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes | Q35780260 | ||
| The Anp genetic variant Rs5068 and circulating levels of natriuretic peptides in patients with chronic heart failure | Q35884575 | ||
| Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence | Q36177005 | ||
| Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. | Q36498070 | ||
| Membrane guanylyl cyclase receptors: an update | Q36525043 | ||
| Atrial natriuretic peptide induces postprandial lipid oxidation in humans | Q36975436 | ||
| Atrial natriuretic peptide is negatively regulated by microRNA-425. | Q37052917 | ||
| The atrial natriuretic peptide genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a Mediterranean population. | Q37106593 | ||
| Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure | Q37148149 | ||
| Enhanced activation of pro-inflammatory cytokines in mice lacking natriuretic peptide receptor-A. | Q37345377 | ||
| Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes | Q37345511 | ||
| The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment | Q37583865 | ||
| M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics | Q37648508 | ||
| Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension. | Q38384610 | ||
| Natriuretic peptide control of energy balance and glucose homeostasis | Q38513704 | ||
| Insulin/glucose induces natriuretic peptide clearance receptor in human adipocytes: a metabolic link with the cardiac natriuretic pathway | Q38776520 | ||
| Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. | Q38885540 | ||
| Metabolic syndrome and risk of cardiovascular disease: a meta-analysis | Q39015722 | ||
| The lipid-mobilizing effect of atrial natriuretic peptide is unrelated to sympathetic nervous system activation or obesity in young men. | Q39563322 | ||
| Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. | Q39750341 | ||
| Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts | Q39799000 | ||
| Attenuated atrial natriuretic peptide-mediated lipolysis in subcutaneous adipocytes of obese type 2 diabetic men. | Q39809555 | ||
| Hypertension Prevalence and Control Among Adults: United States, 2011-2014. | Q40245946 | ||
| Defective Natriuretic Peptide Receptor Signaling in Skeletal Muscle Links Obesity to Type 2 Diabetes | Q40647072 | ||
| Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension | Q42280521 | ||
| Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload | Q42475794 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 13 | |
| P921 | main subject | Natriuretic peptide A | Q302495 |
| cardiovascular disease | Q389735 | ||
| metabolic disease | Q2351083 | ||
| P577 | publication date | 2019-07-02 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease | |
| P478 | volume | 20 |
| Q90304081 | Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics |
| Q97520285 | Merging microarray studies to identify a common gene expression signature to several structural heart diseases |
| Q92702039 | Natriuretic Peptides in the Cardiovascular System: Multifaceted Roles in Physiology, Pathology and Therapeutics |
Search more.